Answers are grounded in this paper and cite their sources.
Lecanemab and other new amyloid-targeting immunotherapies for Alzheimer disease show notable promise but may also pose significant risk for patients.
No takes yet. Share an insight, caveat, or question.
Turk et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: